In line with this, oligomycin treatment significantly reduces Th1 proliferation (149), IL-17α secreting CD3+ T cells, and thereby attenuates TNBS-induced colitis animal model comparable to the group treated with RORγt inhibitor ursolic acid (60) (Figure 6; Table 3). Here, IL17A is linked to colitis.